Laurus Labs is Indian pharma’s dark horse

With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.

This is the third part in our year-end Public Markets Special for 2023. Read more about it here.

Laurus Labs isn’t likely to be top of mind if you’re asked to name a bunch of Indian companies in the pharmaceuticals business. It's probably not high on recall even in its base, Hyderabad, headquarters to several drug manufacturers, including the likes of Dr Reddy’s Laboratories, Aurobindo Pharma and Natco Pharma.

Yet, as of Tuesday, Laurus Labs’s shares are among the most expensive in the industry if you go by the popular valuation metric—the price-to-earnings, or P/E, ratio. At a P/E …


T Surendar

Surendar helps lead the newsroom at The Morning Context as executive editor. Over the years, Surendar has worked in industries from pharmaceuticals to diamonds, as well as a stint as an equity analyst. In his long career as a business journalist, he has led teams at The Times of India, India Today and Fortune India. He was part of the founding team at Forbes India and interned at and published in The Times, London.

Executive Editor